MSI2 and triple-negative breast carcinoma: The finding of MSI2 overexpression is significant as it suggests that MSI2 targeting may disproportionately affect MSI2 high-expressing tumor cells, as has similarly been proposed–and validated–for triple-negative breast cancer (Brücksken et al., 2025).